阿必鲁肽与2型糖尿病合并心血管疾病患者的心血管结局(Harmony Outcomes):一项双盲、随机、安慰剂对照试验
Harmony Outcomes是一项在28个国家610个中心进行的双盲、随机、安慰剂对照试验,纳入40岁及以上2型糖尿病合并心血管疾病的患者9463例,按1:1随机分至阿必鲁肽组(30-50 mg,根据血糖反应和耐受性调整,每周一次皮下注射)或安慰剂组。中位随访1.6年,主要复合终点(首次发生心血管死亡、心肌梗死或卒中)在阿必鲁肽组发生338例(7%),发生率为4.6例/100人年,安慰剂组发生428例(9%),发生率为5.9例/100人年(HR 0.78,95%CI 0.68-0.90),非劣效性p<0.0001,优效性p=0.0006。急性胰腺炎、胰腺癌、甲状腺髓样癌及其他严重不良事件两组无差异。作者认为,在2型糖尿病合并心血管疾病患者中,阿必鲁肽在主要不良心血管事件方面优于安慰剂,基于证据的胰高血糖素样肽1受体激动剂应作为综合策略的一部分以降低心血管事件风险。
要点
- 在2型糖尿病合并心血管疾病患者中,阿必鲁肽组主要复合终点发生338/4731例(7%),发生率4.6例/100人年,安慰剂组428/4732例(9%),发生率5.9例/100人年,HR 0.78(95%CI 0.68-0.90)。
- 阿必鲁肽为非劣效(95%CI上限<1.30,p<0.0001),并达到优效(p=0.0006)。
- 阿必鲁肽30-50 mg每周一次皮下注射,剂量根据血糖反应和耐受性调整,中位随访1.6年。
- 急性胰腺炎(阿必鲁肽组10例 vs 安慰剂组7例)、胰腺癌(6例 vs 5例)、甲状腺髓样癌(两组均为0例)及其他严重不良事件两组无差异。
- 研究者设盲评估的治疗相关死亡:安慰剂组3例(<1%),阿必鲁肽组2例(<1%)。
适用人群与场景
- 40岁及以上、2型糖尿病合并心血管疾病的患者,来自28个国家610个中心。
诊断标准与关键阈值
- 主要复合终点为首次发生心血管死亡、心肌梗死或卒中,在意向治疗人群中评估。
- 非劣效性界值为风险比95%CI上限小于1.30;非劣效确认后预设进行优效性检验。
处置流程与药物剂量
- 阿必鲁肽30-50 mg,根据血糖反应和耐受性调整剂量,每周一次皮下注射,联合标准治疗。
- 安慰剂为匹配体积,每周一次皮下注射,联合标准治疗。
研究设计与关键结果
- 双盲、随机、安慰剂对照试验,纳入9463例患者,阿必鲁肽组4731例,安慰剂组4732例,中位随访1.6年。
- 主要复合终点:阿必鲁肽组338例(7%),发生率4.6例/100人年;安慰剂组428例(9%),发生率5.9例/100人年;HR 0.78(95%CI 0.68-0.90),非劣效性p<0.0001,优效性p=0.0006。
- 急性胰腺炎:阿必鲁肽组10例,安慰剂组7例;胰腺癌:阿必鲁肽组6例,安慰剂组5例;甲状腺髓样癌:两组均为0例;其他严重不良事件两组无差异。
- 研究者设盲评估的治疗相关死亡:安慰剂组3例(<1%),阿必鲁肽组2例(<1%)。
证据类型、等级与局限
- 证据类型:双盲、随机、安慰剂对照试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在2型糖尿病合并心血管疾病患者中,阿必鲁肽在主要不良心血管事件方面优于安慰剂。
- 作者认为,基于证据的胰高血糖素样肽1受体激动剂应作为综合策略的一部分,以降低2型糖尿病合并心血管疾病患者的心血管事件风险。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. We aimed to determine the safety and efficacy of albiglutide in preventing cardiovascular death, myocardial infarction, or stroke.
METHODS: We did a double-blind, randomised, placebo-controlled trial in 610 sites across 28 countries. We randomly assigned patients aged 40 years and older with type 2 diabetes and cardiovascular disease (at a 1:1 ratio) to groups that either received a subcutaneous injection of albiglutide (30-50 mg, based on glycaemic response and tolerability) or of a matched volume of placebo once a week, in addition to their standard care. Investigators used an interactive voice or web response system to obtain treatment assignment, and patients and all study investigators were masked to their treatment allocation. We hypothesised that albiglutide would be non-inferior to placebo for the primary outcome of the first occurrence of cardiovascular death, myocardial infarction, or stroke, which was assessed in the intention-to-treat population. If non-inferiority was confirmed by an upper limit of the 95% CI for a hazard ratio of less than 1·30, closed testing for superiority was prespecified. This study is registered with ClinicalTrials.gov, number NCT02465515.
FINDINGS: Patients were screened between July 1, 2015, and Nov 24, 2016. 10 793 patients were screened and 9463 participants were enrolled and randomly assigned to groups: 4731 patients were assigned to receive albiglutide and 4732 patients to receive placebo. On Nov 8, 2017, it was determined that 611 primary endpoints and a median follow-up of at least 1·5 years had accrued, and participants returned for a final visit and discontinuation from study treatment; the last patient visit was on March 12, 2018. These 9463 patients, the intention-to-treat population, were evaluated for a median duration of 1·6 years and were assessed for the primary outcome. The primary composite outcome occurred in 338 (7%) of 4731 patients at an incidence rate of 4·6 events per 100 person-years in the albiglutide group and in 428 (9%) of 4732 patients at an incidence rate of 5·9 events per 100 person-years in the placebo group (hazard ratio 0·78, 95% CI 0·68-0·90), which indicated that albiglutide was superior to placebo (p<0·0001 for non-inferiority; p=0·0006 for superiority). The incidence of acute pancreatitis (ten patients in the albiglutide group and seven patients in the placebo group), pancreatic cancer (six patients in the albiglutide group and five patients in the placebo group), medullary thyroid carcinoma (zero patients in both groups), and other serious adverse events did not differ between the two groups. There were three (<1%) deaths in the placebo group that were assessed by investigators, who were masked to study drug assignment, to be treatment-related and two (<1%) deaths in the albiglutide group.
INTERPRETATION: In patients with type 2 diabetes and cardiovascular disease, albiglutide was superior to placebo with respect to major adverse cardiovascular events. Evidence-based glucagon-like peptide 1 receptor agonists should therefore be considered as part of a comprehensive strategy to reduce the risk of cardiovascular events in patients with type 2 diabetes.
FUNDING: GlaxoSmithKline.
参考来源
- Hernandez AF, Green JB, Janmohamed S, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018. PMID: 30291013. doi:10.1016/S0140-6736(18)32261-X
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。